Similar to PML silencing (Fig. 6A), treatment with ATO led to p53 upregulation in ccRCC cells (Fig. 7F), suggesting that this compound could be used to unleash the tumor-suppressive functions of wild-type p53 in this tumor type. Here, TP53 is linked to nonpapillary renal cell carcinoma.